These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 28165448)

  • 1. Effective desensitization of donor-specific HLA antibodies using platelet transfusion bearing targeted HLA in a case of HLA-mismatched allogeneic stem cell transplantation.
    Yamashita T; Ikegame K; Kojima H; Tanaka H; Kaida K; Inoue T; Ogawa H
    Bone Marrow Transplant; 2017 May; 52(5):794-796. PubMed ID: 28165448
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute mixed-lineage leukemia treated with desensitization therapy prior to HLA-haploidentical transplantation with high donor-specific antibodies.
    Katsuki K; Tachibana T; Izumi A; Kim K; Suzuki T; Tanaka M; Nakajima H
    Int J Hematol; 2024 Aug; 120(2):256-261. PubMed ID: 38676859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Emergence of donor-derived anti-HLA antibody and subsequent transfusion-refractory thrombocytopenia after allogeneic hematopoietic stem cell transplantation from an HLA-matched sibling donor in a patient with acute myeloid leukemia].
    Uchiyama Y; Hoshino T; Mihara M; Mitsui T; Koiso H; Takizawa M; Yokohama A; Saitoh T; Uchiumi H; Handa H; Tsukamoto N; Murakami H; Nojima Y
    Rinsho Ketsueki; 2013 Feb; 54(2):214-8. PubMed ID: 23470830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloimmune platelet transfusion refractoriness circumvented by allogeneic stem cell transplantation.
    Bonstein L; Stemer G; Dann EJ; Zuckerman T; Fineman R; Haddad N
    Transfusion; 2013 May; 53(5):1019-23. PubMed ID: 22897696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A strategy to reduce donor-specific HLA Abs before allogeneic transplantation.
    Gergis U; Mayer S; Gordon B; Mark T; Pearse R; Shore T; Van Besien K
    Bone Marrow Transplant; 2014 May; 49(5):722-4. PubMed ID: 24535131
    [No Abstract]   [Full Text] [Related]  

  • 6. Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation.
    Toor AA; Choo SY; Little JA
    Bone Marrow Transplant; 2000 Aug; 26(3):315-20. PubMed ID: 10967572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depletion of donor-specific anti-HLA A2 alloantibodies in a hematopoietic cell transplant recipient using directed mismatched platelet transfusions.
    Spriewald BM; Bach C; Zingsem J; Strobel J; Winkler J; Mackensen A; Roesler W
    Bone Marrow Transplant; 2018 Jun; 53(6):791-794. PubMed ID: 29795430
    [No Abstract]   [Full Text] [Related]  

  • 8. [Resuscitation necessitated by a transfusion reaction after HLA mismatched platelets substitution].
    Kuntz BM; Schöttler B; Brüster HT
    Beitr Infusionsther Transfusionsmed; 1994; 32():307-9. PubMed ID: 9480114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretransplant platelet transfusion refractoriness is not associated with platelet nonengraftment in T-replete hematopoietic progenitor cell transplantation for hematologic malignancies.
    Scott A; Baidya S; Butler J; Morris K; Thornton A; Kennedy GA
    Transfusion; 2016 Jan; 56(1):164-9. PubMed ID: 26264674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative donors hematopoietic stem cells transplantation for adults with acute myeloid leukemia: Umbilical cord blood or haploidentical donors?
    Ruggeri A; Ciceri F; Gluckman E; Labopin M; Rocha V;
    Best Pract Res Clin Haematol; 2010 Jun; 23(2):207-16. PubMed ID: 20837332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-HLA antibodies other than against HLA-A, -B, -DRB1 adversely affect engraftment and nonrelapse mortality in HLA-mismatched single cord blood transplantation: possible implications of unrecognized donor-specific antibodies.
    Yamamoto H; Uchida N; Matsuno N; Ota H; Kageyama K; Wada S; Kaji D; Nishida A; Ishiwata K; Takagi S; Tsuji M; Asano-Mori Y; Yamamoto G; Izutsu K; Masuoka K; Wake A; Yoneyama A; Makino S; Taniguchi S
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1634-40. PubMed ID: 24972251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet transfusion refractoriness due to graft-derived anti-HPA-2b production after allogeneic bone-marrow transplantation.
    Taaning E; Jacobsen N
    Transplant Proc; 1994 Jun; 26(3):1826. PubMed ID: 8030157
    [No Abstract]   [Full Text] [Related]  

  • 13. Platelet transfusion refractoriness attributable to HLA antibodies produced by donor-derived cells after allogeneic bone marrow transplantation from one HLA-antigen-mismatched mother.
    Hatakeyama N; Hori T; Yamamoto M; Inazawa N; Iesato K; Miyazaki T; Ikeda H; Tsutsumi H; Suzuki N
    Pediatr Transplant; 2011 Dec; 15(8):E177-82. PubMed ID: 20880381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet transfusion therapy in an alloimmunized patient. The value of crossmatch procedures for donor selection.
    Hecht T; Wolf JL; Mraz L; Scott EP; Patz LD
    JAMA; 1982 Nov; 248(18):2301-3. PubMed ID: 6752444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of HLA Antibodies in HLA Mismatched Allogeneic Hematopoietic Stem Cell Transplantation.
    Zhang X; Wang J; Zhou Z; Zhang Y; Liu H; Tong C; Yu C; Lu Y; Zhao Y; Xiong M; Zhou JR; Juan S; Liu DY; Wei Z; Zhang J; Wu T; Lu DP
    Clin Transpl; 2014; ():245-50. PubMed ID: 26281152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective desensitization for a strong donor-specific HLA antibody in a case of HLA-mismatched allogeneic hematopoietic cell transplantation.
    Misra MK; Xin JJ; Brown NK; Weidner JG; Upchurch RL; Bishop MR; Wool GD; Artz AS; Marino SR
    HLA; 2019 Sep; 94(3):307-311. PubMed ID: 31314169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonal evolution including partial loss of human leukocyte antigen genes favoring extramedullary acute myeloid leukemia relapse after matched related allogeneic hematopoietic stem cell transplantation.
    Stölzel F; Hackmann K; Kuithan F; Mohr B; Füssel M; Oelschlägel U; Thiede C; Röllig C; Platzbecker U; Schetelig J; Illmer T; Schaich M; Seliger B; Hartmann A; Baretton G; Zietz C; Ehninger G; Schrock E; Bornhäuser M
    Transplantation; 2012 Apr; 93(7):744-9. PubMed ID: 22314337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for HLA antibodies in plateletpheresis donors with a history of transfusion or pregnancy.
    De Clippel D; Baeten M; Torfs A; Emonds MP; Feys HB; Compernolle V; Vandekerckhove P
    Transfusion; 2014 Dec; 54(12):3036-42. PubMed ID: 24863861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does donor-recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia?
    Mehta J; Powles R; Sirohi B; Treleaven J; Kulkarni S; Saso R; Tait D; Singhal S
    Bone Marrow Transplant; 2002 May; 29(10):853-9. PubMed ID: 12058235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful engraftment in crossmatch-positive HLA-mismatched peripheral blood stem cell transplantation after depletion of antidonor cytotoxic HLA antibodies with rituximab and donor platelet infusion.
    Narimatsu H; Wake A; Miura Y; Tanaka H; Matsumura T; Takagi S; Kato D; Myojo T; Kusumi E; Masuoka K; Miyakoshi S; Morinaga S; Saji H; Ichinohe T; Taniguchi S
    Bone Marrow Transplant; 2005 Sep; 36(6):555-6. PubMed ID: 16007108
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.